Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
53.5
USD
|
+6.13%
|
|
+17.92%
|
+398.60%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
821
|
547.2
|
495.2
|
2,774
|
-
|
-
|
Enterprise Value (EV)
1 |
821
|
547.2
|
495.2
|
2,774
|
2,774
|
2,774
|
P/E ratio
|
-14.2
x
|
-8.66
x
|
-8.13
x
|
-39.6
x
|
-32.3
x
|
-26.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
226
x
|
63.5
x
|
61.3
x
|
751
x
|
1,015
x
|
274
x
|
EV / Revenue
|
226
x
|
63.5
x
|
61.3
x
|
751
x
|
1,015
x
|
274
x
|
EV / EBITDA
|
-25
x
|
-8.26
x
|
-6.97
x
|
-27.6
x
|
-23.4
x
|
-
|
EV / FCF
|
-44.5
x
|
-8.16
x
|
-
|
-64.4
x
|
-27.6
x
|
-24.4
x
|
FCF Yield
|
-2.25%
|
-12.3%
|
-
|
-1.55%
|
-3.62%
|
-4.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
41,612
|
41,551
|
46,151
|
51,845
|
-
|
-
|
Reference price
2 |
19.73
|
13.17
|
10.73
|
53.50
|
53.50
|
53.50
|
Announcement Date
|
3/18/22
|
3/10/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
3.637
|
8.612
|
8.083
|
3.692
|
2.733
|
10.13
|
EBITDA
1 |
-
|
-32.82
|
-66.25
|
-71.02
|
-100.3
|
-118.6
|
-
|
EBIT
1 |
-
|
-32.93
|
-67.09
|
-72.98
|
-91.2
|
-114.8
|
-136.7
|
Operating Margin
|
-
|
-905.39%
|
-779.04%
|
-902.87%
|
-2,470.16%
|
-4,199.23%
|
-1,349.53%
|
Earnings before Tax (EBT)
1 |
-
|
-32.67
|
-63.06
|
-59.29
|
-67.77
|
-94.01
|
-120.2
|
Net income
1 |
-6.784
|
-32.67
|
-63.06
|
-59.29
|
-72.88
|
-94.86
|
-120.2
|
Net margin
|
-
|
-898.32%
|
-732.22%
|
-733.55%
|
-1,974.07%
|
-3,470.4%
|
-1,186.49%
|
EPS
2 |
-7.416
|
-1.390
|
-1.520
|
-1.320
|
-1.351
|
-1.659
|
-2.000
|
Free Cash Flow
1 |
-
|
-18.46
|
-67.09
|
-
|
-43.07
|
-100.4
|
-113.8
|
FCF margin
|
-
|
-507.51%
|
-779.04%
|
-
|
-1,166.52%
|
-3,673.18%
|
-1,123.55%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/16/21
|
3/18/22
|
3/10/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.616
|
1.589
|
2.365
|
1.813
|
2.845
|
2.048
|
1.057
|
2.517
|
2.461
|
1.252
|
0.8631
|
1.02
|
0.9125
|
-
|
-
|
EBITDA
|
-13.43
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-15.61
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.49
|
-13.54
|
-17.26
|
-18.02
|
-18.27
|
-20.28
|
-20.75
|
-15.81
|
-16.14
|
-20.16
|
-22.26
|
-23.23
|
-25.24
|
-
|
-
|
Operating Margin
|
-834.78%
|
-852.23%
|
-729.85%
|
-994.04%
|
-642.04%
|
-990.28%
|
-1,962.91%
|
-628.25%
|
-655.71%
|
-1,610.3%
|
-2,579.49%
|
-2,278.73%
|
-2,765.88%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.42
|
-13.41
|
-16.89
|
-16.7
|
-16.06
|
-17.46
|
-17.51
|
-11.57
|
-11.76
|
-14.76
|
-14.72
|
-15.22
|
-16.98
|
-
|
-
|
Net income
1 |
-13.42
|
-13.41
|
-16.89
|
-16.7
|
-16.06
|
-17.46
|
-17.51
|
-11.57
|
-11.76
|
-14.76
|
-16.72
|
-17.38
|
-19.62
|
-
|
-
|
Net margin
|
-830.2%
|
-843.93%
|
-714.08%
|
-920.9%
|
-564.67%
|
-852.49%
|
-1,656.39%
|
-459.59%
|
-477.77%
|
-1,178.91%
|
-1,937.06%
|
-1,704.68%
|
-2,150.58%
|
-
|
-
|
EPS
2 |
-0.2900
|
-0.3200
|
-0.4100
|
-0.4000
|
-0.3900
|
-0.4200
|
-0.4200
|
-0.2500
|
-0.2500
|
-0.3000
|
-0.3167
|
-0.3350
|
-0.3800
|
-0.3350
|
-0.3525
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/22
|
5/10/22
|
8/9/22
|
11/10/22
|
3/10/23
|
5/9/23
|
8/8/23
|
11/7/23
|
3/8/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-18.5
|
-67.1
|
-
|
-43.1
|
-100
|
-114
|
ROE (net income / shareholders' equity)
|
-
|
-18.6%
|
-18.4%
|
-
|
-18.3%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-0.7200
|
-1.040
|
-
|
-1.020
|
-0.7100
|
-1.170
|
Capex
1 |
-
|
-
|
-
|
-
|
2
|
1.95
|
2.2
|
Capex / Sales
|
-
|
-
|
-
|
-
|
54.17%
|
71.34%
|
21.72%
|
Announcement Date
|
4/16/21
|
3/18/22
|
3/10/23
|
3/8/24
|
-
|
-
|
-
|
Last Close Price
53.5
USD Average target price
61.5
USD Spread / Average Target +14.95% Consensus |
1st Jan change
|
Capi.
|
---|
| +398.60% | 2.77B | | +43.36% | 54.63B | | -5.31% | 39.92B | | +37.52% | 38.82B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +25.12% | 12.21B | | +0.04% | 12.16B | | +26.04% | 11.94B |
Other Biotechnology & Medical Research
|